Journal Article

One-year follow-up study after patients with severe COVID-19 received human umbilical cord mesenchymal stem cells treatment

Huang, Tingrong, Yan, Jiaxin, Wei, Jing, Cheng, Zhi, Wang, Xueli, Niu, Changming, Feng, Ganzhu, Wang, Yan, Shu, Lei, Wu, Mingjing, Chen, Xiaolin, Ji, Ningfei, Huang, Mao, Cao, Yang, Deng, Kaili, Zheng, You, Shi, Lei, Li, Ruyou

2022

Overview

Background The novel coronavirus is still mutating, and the pandemic continues. Meanwhile, many COVID-19 survivors have residual postinfection clinical manifestations. Human umbilical cord mesenchymal stem cells (hUC-MSCs) have been shown to be effective in the early stages of COVID-19. Objectives The aim of this study was to investigate long-term safety and efficacy of treatment in patients with severe COVID-19 patients who had received hUC-MSCs therapy. Methods Twenty-five discharged patients who had severe COVID-19 (including the standard treatment group and the standard treatment plus hUC-MSCs group) were enrolled in a 1-year follow-up. The assessment considered adverse effects (including effects on liver and kidney function, coagulation, ECG, tumor marker, and so on), pulmonary function, St George’s Respiratory Questionnaire (SGRQ), postinfection sequelae and serum concentration of Krebs von den Lungen-6 (KL-6), malondialdehyde (MDA), H 2 S, carnitine, and N-6 long-chain polyunsaturated fatty acids (N-6 LC-PUFAs). Measurements and main results Pulmonary ventilation function had significantly improved at the 1-year follow-up in both the hUC-MSCs group and the control group compared with the 3-month follow-up ( P  < 0.01). Fatigue (60% [15/25]) remained the most common symptom at the 1-year follow-up. The rate of fatigue relief was significantly reduced in the hUC-MSCs group (25% [2/8]) compared to the control group (76.5% [13/17]) ( P  = 0.028). The level of KL-6 was significantly lower in the hUC-MSCs group (2585.5 ± 186.5 U/ml) than in the control group (3120.7 ± 158.3 U/ml) ( P  < 0.001). Compared with the control group, the hUC-MSCs group had a lower level of MDA (9.27 ± 0.54 vs. 9.91 ± 0.72 nmol/ml, P  = 0.036). No obvious adverse effects were observed in the hUC-MSCs treatment group at 1 year after discharge. Conclusions Intravenous transplantation of hUC-MSCs was a safe approach in the long term in the treatment of patients with severe COVID-19. In addition, hUC-MSCs had a positive effect on postinfection sequelae in COVID-19 survivors. Trial registration Chinese Clinical Trial Registration; ChiCTR2000031494; Registered 02 April 2020—Retrospectively registered, http://www.medresman.org

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: 1-Year follow-up / Biomedical and Life Sciences / Biomedical Engineering and Bioengineering / Blood tests / Care and treatment / Carnitine / Cell Biology / Complications / Coronavirus disease 2019 (COVID-19) / Coronaviruses / COVID-19 / Epidemics / Fatigue / Hospitals / Human umbilical cord mesenchymal stem cells (h-UC-MSCs) / Hydrogen sulfide / Infectious diseases / Intravenous administration / Laboratories / Life Sciences / Liver / Mechanical ventilation / Medical research / Medicine, Experimental / Mesenchymal stem cells / Patients / Polyunsaturated fatty acids / Quality of life / Questionnaires / Regenerative Medicine/Tissue Engineering / Respiratory function / Safety / Sequelae / Severe acute respiratory syndrome coronavirus 2 / Side effects / Stem cell therapy of COVID-19 and other respiratory diseases / Stem Cells / Traditional Chinese medicine / Transplantation / Tumor markers / Tumors / Umbilical cord / Unsaturated fatty acids / Ventilation / Ventilators